| Description |
Vosoritide (BMN 111) is a modified recombinant CNP (C-type natriuretic peptide) analogue, binds to NPR-B (natriuretic peptide receptor type B) and reduces the activity of FGFR3 (fibroblast growth factor receptor 3). Vosoritide can be used in achondroplasia and dwarfism research[1][2][3].
|
| Related Catalog |
|
| In Vitro |
Vosoritide (0.1 μM; 1 h) decreases NPR2 phosphorylation in chondrocytes[2]. Vosoritide (0.1 μM; 6 d) improves chondrocyte differentiation and increases the proliferative growth plate area of cultured Fgfr3Y367C/+ femurs[2]. Vosoritide (10 μM; overnight) reduces ERK1/2 activation in ACH growth-plate chondrocytes[3]. Western Blot Analysis[2] Cell Line: Chondrocyte cultures Concentration: 0.1 μM Incubation Time: 1 hour Result: Led to reduction in NPR2 phosphorylation. Western Blot Analysis[3] Cell Line: Chondrocyte Concentration: 10 μM Incubation Time: Overnight Result: Prevented FGF-mediated increase in ERK1/2 phosphorylation.
|
| In Vivo |
Vosoritide (subcutaneous injection; 800 μg/kg; once daily; 20 d) treatment leads to improvement in skeletal parameters in Fgfr3 gain-of-function mutation mouse[3]. Animal Model: Fgfr3Y367C/+ mice[3] Dosage: 800 μg/kg Administration: Subcutaneous injection; 800 μg/kg; once daily; 20 days Result: Observed phenotypic changes including flattening of the skull, elongation of the snout, improvement of the anterior crossbite, larger paws and digits, and longer and straightened tibias and femurs.
|
